Anika Therapeutics (ANIK) Gross Profit (2016 - 2026)
Anika Therapeutics has reported Gross Profit over the past 17 years, most recently at $19.0 million for Q1 2026.
- Quarterly Gross Profit rose 29.4% to $19.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $68.1 million through Mar 2026, down 4.99% year-over-year, with the annual reading at $63.8 million for FY2025, 16.04% down from the prior year.
- Gross Profit was $19.0 million for Q1 2026 at Anika Therapeutics, down from $19.2 million in the prior quarter.
- Over five years, Gross Profit peaked at $29.0 million in Q2 2023 and troughed at $3.8 million in Q4 2022.
- The 5-year median for Gross Profit is $19.2 million (2025), against an average of $18.5 million.
- Year-over-year, Gross Profit tumbled 79.18% in 2022 and then surged 196.66% in 2024.
- A 5-year view of Gross Profit shows it stood at $3.8 million in 2022, then skyrocketed by 52.93% to $5.8 million in 2023, then soared by 196.66% to $17.1 million in 2024, then increased by 11.99% to $19.2 million in 2025, then fell by 0.95% to $19.0 million in 2026.
- Per Business Quant, the three most recent readings for ANIK's Gross Profit are $19.0 million (Q1 2026), $19.2 million (Q4 2025), and $15.6 million (Q3 2025).